SEC, US Trustee Object To Releases In Amyris' Ch. 11 Plan

By Ben Zigterman · January 18, 2024, 6:57 PM EST

The U.S. Securities and Exchange Commission and the U.S. Trustee's Office have expressed new concerns about nonconsensual third-party releases in biotechnology company Amyris' Chapter 11 plan, arguing that such releases are...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Bankruptcy Scorecard

Summary

Synthesized biologicals producer Amyris filed for Chapter 11 bankruptcy protection in August with more than $1.1 billion in debt and plans to sell parts of its business. It received court approval of its $190 million debtor-in-possession loan.

Case Number

1:23-bk-11131

Judge

Thomas M. Horan

Venue

U.S. Bankruptcy Court for the District of Delaware

Capital Structure

Total Liabilities:

$1.1 billion

View Full Scorecard

Documents

Related Sections

Case Information

Case Title

Amyris, Inc.

Case Number

1:23-bk-11131

Court

Delaware

Nature of Suit

Date Filed

August 09, 2023

Recent Articles By Ben